Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
批准号:
9535519
负责人:
ALBERT R LA SPADA
金额:
$49.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-30 至 2021-08-31
关键词:
ActinsAndrogen AntagonistsAndrogen ReceptorAntisense OligonucleotidesAutophagocytosisAutophagosomeBacterial Artificial ChromosomesBioinformaticsBiologicalCatalogingCatalogsCell Culture TechniquesCell modelCellsCoculture TechniquesComplexDefectDevelopmentDiseaseExcisionExonsFunctional disorderGene ExpressionGenetic TranscriptionGoalsHumanInheritedInvestigationKennedy SyndromeKnock-in MouseLigandsLinkLongevityLoxP-flanked alleleLumbar spinal cord structureLysosomesModelingMolecularMotorMotor Neuron DiseaseMotor NeuronsMusMuscleMuscle FibersNerve DegenerationNeurodegenerative DisordersNeuromuscular DiseasesNuclearPathogenesisPathologicPathway interactionsPatientsPerformancePeripheralPhenotypeProcessProteinsReceptor GeneRoleSiteSkeletal MuscleStem cellsToxic effectTranscriptional ActivationTranscriptional RegulationTransgenesTransgenic MiceValidationWorkcell typedisease phenotypegene repressionin vitro Modelin vivoinduced pluripotent stem cellmolecular pathologymotor controlmotor deficitmotor neuron degenerationmouse modelmutantnerve stem cellneuromuscularnovelpolyglutaminepreventquadriceps musclereceptorreceptor expressionskeletalspinal and bulbar muscular atrophystemtranscription factortranscriptometranscriptome sequencingtransgene expression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy's disease) is an inherited neuromuscular
disorder characterized by lower motor neuron degeneration. SBMA is caused by CAG/polyglutamine repeat
expansions in the human androgen receptor gene, and is one of nine neurodegenerative disorders that result
from polyglutamine (polyQ) proteins. We set out to determine the cellular and molecular basis of SBMA
disease pathogenesis. To achieve these goals, we created novel mouse models of SBMA, including BAC
transgenic mice containing a floxed first exon (i.e. the BAC fxAR121 line) to permit cell-type specific excision of
the AR transgene. We crossed BAC fxAR121 mice with Human Skeletal Actin (HSA)-Cre mice, and
documented that excision of the AR transgene from skeletal muscle prevented development of both systemic
and neuromuscular SBMA phenotypes, revealing a crucial role for muscle expression of mutant polyQ-AR in
SBMA motor neuron degeneration. We produced antisense oligonucleotides (ASOs) directed against AR, and
upon peripheral delivery, we demonstrated that peripheral suppression of polyQ-AR rescued motor deficits,
reversed alterations in muscle gene expression, and markedly extended lifespan in SBMA mice. These
provocative findings implicate skeletal muscle as a key site for SBMA disease pathogenesis. To determine the
contribution of motor neurons (MNs) to SBMA, we crossed BAC fxAR121 mice with vChAT-Cre mice, and
noted a modest, but significant improvement in motor performance in bigenic mice. Hence, SBMA disease
pathogenesis involves a convergence of alterations stemming from pathological interactions between skeletal
muscle and MNs. We also uncovered autophagy dysregulation as a defining feature of SBMA MN disease by
analyzing in vivo and in vitro models, including a human SBMA stem cell model. These studies revealed
abnormalities of autophagosome maturation and lysosome fusion in SBMA cell models, mice, and neuronal
progenitor cells derived from iPSCs, thereby linking autophagy dysfunction to the onset of SBMA. To delineate
the basis of this effect, we considered the transcriptional regulation of autophagy, uncovered an interaction
between AR and transcription factor EB (TFEB), and determined that TFEB dysregulation accounts for
autophagy defects in SBMA. In this project, we will define the molecular contributions of skeletal muscle and
MNs to SBMA by performing transcriptome analysis in our various conditional deletion SBMA mouse models;
delineate the cellular basis for MN demise by developing skeletal muscle and MN models of SBMA from
patient iPSCs, and determining if non-cell autonomous toxicity can be recapitulated in these stem cell models;
and define the basis for AR co-activation and polyQ-AR repression of TFEB by identifying co-regulators whose
interactions and functions with AR and TFEB in complex are altered in the presence of polyQ-AR.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular genetic regulation of autophagy in health and neurodegenerative disease
-
批准号:10367877
-
项目类别:
-
资助金额:$6.02万
-
财政年份:2022
-
负责人:ALBERT R LA SPADA
-
依托单位:
La Spada Outstanding Investigator Award
-
批准号:10227293
-
项目类别:
-
资助金额:$99.54万
-
财政年份:2021
-
负责人:ALBERT R LA SPADA
-
依托单位:
La Spada Outstanding Investigator Award
-
批准号:10401437
-
项目类别:
-
资助金额:$116.23万
-
财政年份:2021
-
负责人:ALBERT R LA SPADA
-
依托单位:
La Spada Outstanding Investigator Award
-
批准号:10618880
-
项目类别:
-
资助金额:$116.23万
-
财政年份:2021
-
负责人:ALBERT R LA SPADA
-
依托单位:
La Spada Outstanding Investigator Award
-
批准号:10652719
-
项目类别:
-
资助金额:$39.24万
-
财政年份:2021
-
负责人:ALBERT R LA SPADA
-
依托单位:
Ataxia Investigators Meeting 8: Leveraging Therapeutic Opportunity into Novel Treatment Paradigms
-
批准号:9913421
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2020
-
负责人:ALBERT R LA SPADA
-
依托单位:
Deconstructing the cellular and molecular basis of SBMA motor neuron disease: From mechanism to therapy
-
批准号:10355757
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2016
-
负责人:ALBERT R LA SPADA
-
依托单位:
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease
-
批准号:8774128
-
项目类别:
-
资助金额:$49.51万
-
财政年份:2014
-
负责人:ALBERT R LA SPADA
-
依托单位:
Ataxin-7 oligonucleotide knock-down to treat SCA7 retinal and cerebellar disease
-
批准号:9321472
-
项目类别:
-
资助金额:$24.41万
-
财政年份:2014
-
负责人:ALBERT R LA SPADA
-
依托单位:
Antisense oligonucleotide knock-down of ataxin-7 in a SCA7 mouse model
-
批准号:8468068
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2012
-
负责人:ALBERT R LA SPADA
-
依托单位:
Antisense oligonucleotide knock-down of ataxin-7 in a SCA7 mouse model
-
批准号:8551817
-
项目类别:
-
资助金额:$18.7万
-
财政年份:2012
-
负责人:ALBERT R LA SPADA
-
依托单位:
MITOCHONDRIAL DYSFUNCTION IN NNAD MUTANT FLIES AND PURKINJE CELL DEGENERATION
-
批准号:8365864
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2011
-
负责人:ALBERT R LA SPADA
-
依托单位:
MITOCHONDRIAL DYSFUNCTION IN NNAD MUTANT FLIES AND PURKINJE CELL DEGENERATION
-
批准号:8171438
-
项目类别:
-
资助金额:$0.14万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
-
批准号:8417674
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
-
批准号:8448969
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
Neuronal RNA processing defects in ALS4 caused by SETX mutations
-
批准号:8310150
-
项目类别:
-
资助金额:$29.62万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
-
批准号:8016623
-
项目类别:
-
资助金额:$33.12万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
-
批准号:8220883
-
项目类别:
-
资助金额:$33.12万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Hungtington's disease neuropatholog
-
批准号:7892074
-
项目类别:
-
资助金额:$33.8万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位:
The PPAR-delta pathway in neural function and Huntington's disease neuropathology
-
批准号:9113786
-
项目类别:
-
资助金额:$47.11万
-
财政年份:2010
-
负责人:ALBERT R LA SPADA
-
依托单位: